Photocure ASA
PHO
Rank in Stocks
#18849
Photocure ASA is a specialized pharmaceutical enterprise focused on the... Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.
Share Price
$4.48
Last synced: 2026-11-09
Market Cap
$120.76M
Change (1 day)
-5.01%
Change (1 year)
-24.43%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Photocure ASA (PHO)
Category
Healthcare
EPS for Photocure ASA (PHO)
EPS as of September 2026 TTM: $0.20
According to Photocure ASA's latest financial reports, its current EPS (TTM) is $0.20. At the end of 2025 the company had an EPS of $-0.01, an increase over its 2024 EPS of $-0.02.
EPS history for Photocure ASA from 2002 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.20 | -2,088.00% |
| 2025 | $-0.01 | -62.00% |
| 2024 | $-0.02 | -528.57% |
| 2023 | 0.00 | -101.29% |
| 2022 | $-0.27 | 108.74% |
| 2021 | $-0.13 | 23.72% |
| 2020 | $-0.11 | -162.44% |
| 2019 | $0.17 | -184.53% |
| 2018 | $-0.20 | 1.84% |
| 2017 | $-0.20 | -203.26% |
| 2016 | $0.19 | -199.32% |
| 2015 | $-0.19 | 22.88% |
| 2014 | $-0.16 | -65.97% |
| 2013 | $-0.46 | 13.17% |
| 2012 | $-0.40 | 590.77% |
| 2011 | $-0.06 | -140.63% |
| 2010 | $0.14 | -94.13% |
| 2009 | $2.45 | -688.93% |
| 2008 | $-0.42 | -33.64% |
| 2007 | $-0.63 | -198.40% |
| 2006 | $0.64 | -298.66% |
| 2005 | $-0.32 | -24.06% |
| 2004 | $-0.42 | 15.40% |
| 2003 | $-0.37 | -53.87% |
| 2002 | $-0.79 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 7,777.26% |
US
|
|
| $-7.07 | -3,656.34% |
US
|
|
| $-5.29 | -2,760.97% |
AU
|
|
| $12.88 | 6,378.92% |
BE
|
|
| $21.56 | 10,745.07% |
NL
|
Questions about Photocure ASA's earnings per share (EPS)
What is Photocure ASA's earnings per share (EPS)?
Photocure ASA's earnings per share (EPS) over the last twelve months is $0.20, as of Sep 2026.
What was Photocure ASA's earnings per share (EPS) in 2025?
In 2025, Photocure ASA's earnings per share (EPS) was $-0.01, compared with $-0.02 in 2024.
How has Photocure ASA's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Photocure ASA's earnings per share (EPS) was highest in 2023 (0.00) and lowest in 2022 ($-0.27).
How does Photocure ASA's earnings per share (EPS) compare with similar companies?
Photocure ASA's earnings per share (EPS) ($0.20) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.